Italia markets close in 4 hours 10 minutes

TARS Jan 2025 25.000 put

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
3,90000,0000 (0,00%)
In data: 10:03AM EDT. Mercato aperto.
Schermo intero
Chiusura precedente3,9000
Aperto3,9000
Denaro0,0000
Domanda0,0000
Prezzo d'esercizio25,00
Scadenza2025-01-17
Min-Max giorno3,9000 - 3,9000
Contratto - Min-MaxN/D
Volume2
Open Interest100
  • GlobeNewswire

    Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis

    IRVINE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, MD, PhD, Chief Executive Officer and Chairman, will ring the closing bell at the Nasdaq Stock Market on Wednesday, September 6, 2023. The event marks the launch of XDEMVY™, which is now available at pharmacies nationwi

  • GlobeNewswire

    Tarsus to Present at Upcoming Investor Conferences

    IRVINE, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, and Jeff Farrow, Chief Financial and Strategy Officer, will participate in the following conferences, both located in New York City, NY: H.C. Wainwright 25th Annual Glo

  • GlobeNewswire

    Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis

    Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available via prescription from an eye care provider Sales force deployed, calling on ophthalmologists and optometrists nationwide IRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology